CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

/in

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program Barcelona, Spain – […]

Read more

Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman

/in

Dr. Blackman is an Entrepreneur-in-Residence at Google Ventures and a former senior pharma executive with a track record of leading the development of innovative cancer therapies  Oncology expertise spans proof-of-biology studies, biomarker development, and clinical-stage decision-making from first-in-human studies through approval London, UK, 9 September 2025 – Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate […]

Read more

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth

/in

Funding enables AMSilk to scale industrial production and meet global customer demand for biotech produced silk-based protein materials The financing round was led by existing investor ATHOS (AT Newtec), with strong participation from fellow existing investors MIG Capital and Novo Holdings The total EUR 52M includes EUR 30M in cash and EUR 22M in convertible […]

Read more

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension

/in

Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282 Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors  Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops […]

Read more

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

/in

Suresnes (France), September 8, 2025 – Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition of KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD). This acquisition demonstrates Servier’s […]

Read more
© Optimum Strategic Communications.